JP2015522648A - 焙煎抽出物およびキサントフモールを含む組成物の使用 - Google Patents
焙煎抽出物およびキサントフモールを含む組成物の使用 Download PDFInfo
- Publication number
- JP2015522648A JP2015522648A JP2015523566A JP2015523566A JP2015522648A JP 2015522648 A JP2015522648 A JP 2015522648A JP 2015523566 A JP2015523566 A JP 2015523566A JP 2015523566 A JP2015523566 A JP 2015523566A JP 2015522648 A JP2015522648 A JP 2015522648A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- roasted
- composition
- treatment
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YKGCBLWILMDSAV-GOSISDBHSA-N Isoxanthohumol Natural products O(C)c1c2C(=O)C[C@H](c3ccc(O)cc3)Oc2c(C/C=C(\C)/C)c(O)c1 YKGCBLWILMDSAV-GOSISDBHSA-N 0.000 title claims abstract description 173
- FUSADYLVRMROPL-UHFFFAOYSA-N demethylxanthohumol Natural products CC(C)=CCC1=C(O)C=C(O)C(C(=O)C=CC=2C=CC(O)=CC=2)=C1O FUSADYLVRMROPL-UHFFFAOYSA-N 0.000 title claims abstract description 173
- UVBDKJHYMQEAQV-UHFFFAOYSA-N xanthohumol Natural products OC1=C(CC=C(C)C)C(OC)=CC(OC)=C1C(=O)C=CC1=CC=C(O)C=C1 UVBDKJHYMQEAQV-UHFFFAOYSA-N 0.000 title claims abstract description 173
- 235000008209 xanthohumol Nutrition 0.000 title claims abstract description 173
- ORXQGKIUCDPEAJ-YRNVUSSQSA-N xanthohumol Chemical compound COC1=CC(O)=C(CC=C(C)C)C(O)=C1C(=O)\C=C\C1=CC=C(O)C=C1 ORXQGKIUCDPEAJ-YRNVUSSQSA-N 0.000 title claims abstract description 173
- 239000000284 extract Substances 0.000 title claims abstract description 98
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 49
- 201000011510 cancer Diseases 0.000 claims abstract description 35
- 238000011282 treatment Methods 0.000 claims abstract description 27
- 230000002265 prevention Effects 0.000 claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 13
- 235000008694 Humulus lupulus Nutrition 0.000 claims abstract description 11
- 108010057466 NF-kappa B Proteins 0.000 claims abstract description 10
- 102000003945 NF-kappa B Human genes 0.000 claims abstract description 10
- 230000001833 anti-estrogenic effect Effects 0.000 claims abstract description 10
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 10
- 230000002503 metabolic effect Effects 0.000 claims abstract description 10
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 9
- 230000004913 activation Effects 0.000 claims abstract description 7
- 229940011871 estrogen Drugs 0.000 claims abstract description 7
- 239000000262 estrogen Substances 0.000 claims abstract description 7
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 6
- 229940046836 anti-estrogen Drugs 0.000 claims abstract description 5
- 239000000328 estrogen antagonist Substances 0.000 claims abstract description 5
- 239000004037 angiogenesis inhibitor Substances 0.000 claims abstract description 4
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 4
- 235000006708 antioxidants Nutrition 0.000 claims abstract description 4
- 239000000729 antidote Substances 0.000 claims abstract description 3
- 208000015181 infectious disease Diseases 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims description 25
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 18
- 235000013339 cereals Nutrition 0.000 claims description 17
- 244000299461 Theobroma cacao Species 0.000 claims description 15
- 235000016213 coffee Nutrition 0.000 claims description 15
- 235000013353 coffee beverage Nutrition 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 12
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 11
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 claims description 11
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 claims description 11
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 11
- 235000001046 cacaotero Nutrition 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 235000009470 Theobroma cacao Nutrition 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 231100000024 genotoxic Toxicity 0.000 claims description 3
- 230000001738 genotoxic effect Effects 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 231100000586 procarcinogen Toxicity 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 claims description 2
- 238000000527 sonication Methods 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 230000002072 anti-mutant effect Effects 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000002592 antimutagenic agent Substances 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 abstract description 10
- 231100000357 carcinogen Toxicity 0.000 abstract description 7
- 239000003183 carcinogenic agent Substances 0.000 abstract description 7
- 230000003091 anti-genotoxic effect Effects 0.000 abstract description 6
- 230000002790 anti-mutagenic effect Effects 0.000 abstract description 6
- 230000006907 apoptotic process Effects 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 5
- 230000001939 inductive effect Effects 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 244000025221 Humulus lupulus Species 0.000 description 38
- 230000000694 effects Effects 0.000 description 38
- 235000013305 food Nutrition 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000004614 tumor growth Effects 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- 239000003651 drinking water Substances 0.000 description 7
- 235000020188 drinking water Nutrition 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000000840 anti-viral effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 230000033115 angiogenesis Effects 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 235000013405 beer Nutrition 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000000711 cancerogenic effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 230000001772 anti-angiogenic effect Effects 0.000 description 4
- 238000001784 detoxification Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000006882 induction of apoptosis Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 241001432959 Chernes Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000005748 tumor development Effects 0.000 description 3
- WCBPJVKVIMMEQC-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine Chemical group [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 WCBPJVKVIMMEQC-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 2
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001399 anti-metabolic effect Effects 0.000 description 2
- 230000003262 anti-osteoporosis Effects 0.000 description 2
- 230000002141 anti-parasite Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 150000001789 chalcones Chemical class 0.000 description 2
- 235000005513 chalcones Nutrition 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000008821 health effect Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VMSLCPKYRPDHLN-UHFFFAOYSA-N (R)-Humulone Chemical compound CC(C)CC(=O)C1=C(O)C(CC=C(C)C)=C(O)C(O)(CC=C(C)C)C1=O VMSLCPKYRPDHLN-UHFFFAOYSA-N 0.000 description 1
- 238000010953 Ames test Methods 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 238000011735 C3H mouse Methods 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241001660687 Xantho Species 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 238000013124 brewing process Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 231100000170 comet assay Toxicity 0.000 description 1
- 238000003927 comet assay Methods 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002718 inhibitory effect on inflammation Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229930008679 prenylflavonoid Natural products 0.000 description 1
- 150000007951 prenylflavonoids Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000020015 schwarzbier Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
Abstract
Description
(i)がんの治療および/または予防に使用するための、および/または
(ii)粗鬆症の治療および/または予防に使用するための、および/または
(iii)メタボリック・シンドロームの治療および/または予防に使用するための、および/または
(iv)糖尿病の治療および/または予防に使用するための、および/または
(v)(単一または複数種の)循環器系疾患の治療および/または予防に使用するための、および/または
(vi)抗−酸化剤として使用するための、および/または
(vii)解毒剤、好ましくは発がん物質解毒化酵素誘導剤として使用するための、および/または
(viii)前発がん物質の代謝活性化を阻害するための、および/または
(ix)抗−変異原および/または抗−遺伝毒性剤として使用するための、および/または
(x)抗−エストロゲンおよび/またはエストロゲン剤として使用するための、および/または
(xi)アポトーシスを誘導するための、および/または
(xii)抗−血管新生剤として使用するための、および/または
(xiii)抗−炎症剤として使用するための、および/または
(xiv)NF−κBを阻害するための、および/または
(xv)抗菌剤として使用するための、
好ましくは治療上有効な量の、キサントフモール(XN)を含む組成物、好ましくは医薬組成物であって、および/または
ここに該組成物は、(a)焙煎抽出物および(b)キサントフモール、好ましくはキサントフモールを含むホップ抽出物を含むかまたはそれらからのみなり、および/またはここに該組成物は、(a)焙煎抽出物および(b)XNまたは、好ましくはキサントフモールを含むホップ抽出物を混合することによって得ることができるかまたは得られる該組成物、によって満たされる。
−XNと焙煎抽出物とを混合し、ここに焙煎抽出物は好ましくは粗く粉砕したかまたは粉砕していない焙煎モルト、穀類、コーヒーまたはカカオの低温抽出物または高温抽出物よりなる群から選択され、
但し、XNは純粋なXN、または合成的に生成したXNおよび/またはホップに由来しないものである。
ここに該方法には以下の工程が含まれる:
−XNと焙煎抽出物とを混合すること、ここに焙煎抽出物は好ましくは粗く粉砕したかまたは粉砕していない焙煎モルト、穀類、コーヒーまたはカカオの低温抽出物または高温抽出物からなる群より選択され、
但し、XNは純粋なXN、または合成的に生成したXNおよび/またはホップに由来しないものである。
議会の方法に従って1.9 kgの焙煎オオムギモルト(Carafa(TM)、タイプ2、Fa.Weyermann,Bamberg)および0.1 kgのピルゼン型モルトを含むモルトを醸造し、ついでマッシュを分離した後、焙煎モルトを煮沸している間にXNに富む25 g/lのホップ抽出物を添加した(XanthoExtrakt,Simon H.Steiner Hopfen GmbH,XN 2.0%)。高温のトラブ(trub)を分離し、珪藻土を用いて分離した後に、XNを含む焙煎モルトを減圧下(in vacuo)(200 mbar、55℃)でほぼ50% w/wの正確な含有量まで濃縮した。シロップ状の抽出物(「密度1.25」kg/l)は、ほぼ1320 mg/kgのXNの含有量を有する。望ましい場合、XNを含む焙煎モルト抽出物は、いずれの従来の医薬担体および添加剤と直接的に混合することができる。
Claims (14)
- (i)がんの治療および/または予防に使用するための、および/または
(ii)骨粗鬆症の治療および/または予防に使用するための、および/または
(iii)メタボリック・シンドロームの治療および/または予防に使用するための、および/または
(iv)糖尿病の治療および/または予防に使用するための、および/または
(v)循環器系疾患(または複数の循環器系疾患)の治療および/または予防に使用するための、および/または
(vi)抗−酸化剤として使用するための、および/または
(vii)解毒剤として使用するための、および/または
(viii)前発がん物質の代謝活性化を阻害するための、および/または
(ix)抗−変異原および/または抗−遺伝毒性剤として使用するための、および/または
(x)抗−エストロゲンおよび/またはエストロゲン剤として使用するための、および/または
(xi)アポトーシスを誘導するための、および/または
(xii)抗−血管新生剤として使用するための、および/または
(xiii)抗−炎症剤として使用するための、および/または
(xiv)NF−κBを阻害するための、および/または
(xv)感染症(または複数の感染症)の治療および/または予防において、特に抗菌剤として使用するための、好ましくは治療上有効な量でキサントフモール(XN)を含む組成物、好ましくは医薬組成物であって、
ここに、組成物は、(a)焙煎抽出物および(b)XN、好ましくはXNを含むホップ抽出物を含むかまたはそれらからなり、および/または該組成物は、(a)焙煎抽出物および(b)XN、好ましくはXNを含むホップ抽出物を混合することによって得ることができるかまたは得られる該組成物。 - 組成物が少なくとも10 mg/kg、好ましくは少なくとも20 mg/kg、好ましくは少なくとも50 mg/kg、好ましくは少なくとも200 mg/kgのXN含有量を有し、および/または焙煎抽出物の量がXNの治療効果(または複数の治療効果)を高めるのに、好ましくは相乗的に高めるのに十分である、請求項1記載の組成物。
- 焙煎抽出物が粗く粉砕したまたは粉砕していない焙煎モルト、穀類、コーヒーまたはカカオよりなる群から選択される、請求項1または2記載の組成物。
- 組成物が各々、XNまたはXNを含むホップ抽出物を、粗く粉砕したまたは粉砕していない焙煎モルト、穀類、コーヒーまたはカカオからの低温抽出物または高温抽出物からなる群より選択される焙煎抽出物と混合する工程を含む方法によって得ることができるかまたは得られる、請求項1〜3のいずれか1項に記載の組成物。
- 使用したXNを含むホップ抽出物が、0.5〜99% w/w(重量/重量%)の範囲のXNの含有量を有する、請求項4記載の組成物。
- XNを含むホップ抽出物を焙煎抽出物と混合した後に、得られた混合物を好ましくは蒸発、凍結乾燥または減圧下で40〜50% w/w(重量/重量%)、特に47〜48% w/w(重量/重量%)の乾燥物質(dry matter)まで濃縮する、請求項4または5記載の組成物。
- さらに、好ましくは加熱、攪拌、混合、振盪、超音波処理、交流の印加および/または分散手段を用いた処理によって、XNを溶解するためのエタノールにホップ抽出物を(前−)溶解する工程を含む、請求項4〜6のいずれか1項に記載の組成物。
- XNの1またはそれを超える治療効果、好ましくは請求項1に記載の1、2以上のまたはすべての治療効果を高める、好ましくは相乗的に高めるための、焙煎抽出物の使用。
- XNがホップ抽出物の形成でまたは成分として存在する、請求項8記載の使用。
- 焙煎抽出物が、粗く粉砕したまたは粉砕していない焙煎モルト、穀類、コーヒーまたはカカオの低温抽出物または高温抽出物よりなる群から選択される、請求項8または9記載の使用。
- 焙煎抽出物ならびにXNの両方または各々、ホップ抽出物が医薬組成物の成分である、請求項8〜10のいずれか1項に記載の使用。
- XNの1またはそれを超える治療効果を高めるための、好ましくは相乗的に高めるための方法であって、該方法が以下の工程:
−XNを焙煎抽出物と混合する、該焙煎抽出物は、好ましくは粗く粉砕したまたは粉砕していない焙煎モルト、穀類、コーヒーまたはカカオの低温抽出物または高温抽出物よりなる群から選択される、を含むが、
但し、XNは純粋なXN、または合成的に生成したXNであり、および/またはホップに由来しない、該方法。 - 組成物、好ましくは医薬組成物を製造する方法であって、以下の工程:
−XNを焙煎抽出物と混合する、該焙煎抽出物は好ましくは粗く粉砕したまたは粉砕していない焙煎モルト、穀類、コーヒーまたはカカオの低温抽出物または高温抽出物よりなる群から選択される、を含むが、
但し、XNは純粋なXN、または合成的に生成したXNであり、および/またはホップに由来しない、該方法。 - 焙煎抽出物およびXNを含むかまたはそれらからのみなる組成物、好ましくは医薬組成物であって、該焙煎抽出物は好ましくは粗く粉砕したまたは粉砕していない焙煎モルト、穀類、コーヒーまたはカカオの低温抽出物または高温抽出物よりなる群から選択され、XNは純粋なXN、または合成的に生成したXNであり、および/またはホップに由来しない、該組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102012014745 | 2012-07-26 | ||
DE102012014745.7 | 2012-07-26 | ||
PCT/EP2013/065804 WO2014016409A1 (en) | 2012-07-26 | 2013-07-26 | Uses of compositions containing a roasted extract and xanthohumol |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018000662A Division JP2018087195A (ja) | 2012-07-26 | 2018-01-05 | 焙煎抽出物およびキサントフモールを含む組成物の使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015522648A true JP2015522648A (ja) | 2015-08-06 |
JP6668073B2 JP6668073B2 (ja) | 2020-03-18 |
Family
ID=48906244
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015523566A Active JP6668073B2 (ja) | 2012-07-26 | 2013-07-26 | 焙煎抽出物およびキサントフモールを含む組成物の使用 |
JP2018000662A Pending JP2018087195A (ja) | 2012-07-26 | 2018-01-05 | 焙煎抽出物およびキサントフモールを含む組成物の使用 |
JP2019236439A Active JP7493333B2 (ja) | 2012-07-26 | 2019-12-26 | 焙煎抽出物およびキサントフモールを含む組成物の使用 |
JP2022060371A Pending JP2022104969A (ja) | 2012-07-26 | 2022-03-31 | 焙煎抽出物およびキサントフモールを含む組成物の使用 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018000662A Pending JP2018087195A (ja) | 2012-07-26 | 2018-01-05 | 焙煎抽出物およびキサントフモールを含む組成物の使用 |
JP2019236439A Active JP7493333B2 (ja) | 2012-07-26 | 2019-12-26 | 焙煎抽出物およびキサントフモールを含む組成物の使用 |
JP2022060371A Pending JP2022104969A (ja) | 2012-07-26 | 2022-03-31 | 焙煎抽出物およびキサントフモールを含む組成物の使用 |
Country Status (14)
Country | Link |
---|---|
US (1) | US9782362B2 (ja) |
EP (1) | EP2877167B1 (ja) |
JP (4) | JP6668073B2 (ja) |
KR (2) | KR20150036604A (ja) |
CN (2) | CN104507463A (ja) |
BR (1) | BR112015001595A2 (ja) |
CA (1) | CA2880108C (ja) |
DK (1) | DK2877167T3 (ja) |
ES (1) | ES2822575T3 (ja) |
HU (1) | HUE052388T2 (ja) |
IN (1) | IN2015DN01204A (ja) |
PL (1) | PL2877167T3 (ja) |
WO (1) | WO2014016409A1 (ja) |
ZA (1) | ZA201500598B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201700096298A1 (it) * | 2017-08-25 | 2019-02-25 | Penta Holding | Metodo per la produzione di una composizione polifenolica a partire da malto d’orzo |
CN108524476B (zh) * | 2018-07-09 | 2020-07-24 | 南京农业大学 | 黄腐酚在制备抗猪流行性腹泻病毒药物中的用途 |
PL429672A1 (pl) * | 2019-04-17 | 2020-10-19 | Bioxan Spółka Z Ograniczoną Odpowiedzialnością | Preparat zawierający ksantohumol i zastosowanie ksantohumolu |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004089359A1 (ja) * | 2003-04-08 | 2004-10-21 | Kirin Beer Kabushiki Kaisha | 骨密度減少の抑制または予防用組成物および飲食品 |
JP2006306800A (ja) * | 2005-04-28 | 2006-11-09 | Kirin Brewery Co Ltd | ファルネソイドx受容体活性化剤 |
JP2008524299A (ja) * | 2004-12-22 | 2008-07-10 | テーアー−クサン アーゲー | キサントフモールを含む天然抽出物、およびその製造方法およびそれから製造される製品 |
JP2008532558A (ja) * | 2005-03-25 | 2008-08-21 | ウニベルズィタイト・ヘント | フラボノイド類の酵素的脱メチル化 |
JP2009502973A (ja) * | 2005-07-29 | 2009-01-29 | バイオアクティブズ,インコーポレイティド | プレニルフラボノイド製剤 |
JP2009504657A (ja) * | 2005-08-09 | 2009-02-05 | メタプロテオミクス,エルエルシー | ホップ及びアカシア産物によるプロテインキナーゼ調節 |
JP2010513360A (ja) * | 2006-12-22 | 2010-04-30 | ジョー. バース ウント ソーン ゲーエムベーハー ウントコー. カーゲー | 肝疾患を予防および/または制御するための、キサントフモールまたはイソキサントフモールの活性物質としての使用 |
JP2010536772A (ja) * | 2007-08-15 | 2010-12-02 | フラクサン ゲゼルシャフト ミット ベシュレンクテル ハフツング アンド カンパニー ケージー | キサントフモールに富んだホップ抽出物 |
JP2011513308A (ja) * | 2008-02-27 | 2011-04-28 | フラクサン ゲーエムベーハー ウント コー. カーゲー | キサントフモール−シクロデキストリン複合体を含有する新規な組成物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07285856A (ja) | 1994-04-21 | 1995-10-31 | Hoechst Japan Ltd | 骨粗鬆症治療剤 |
DE19939350B4 (de) | 1999-08-19 | 2005-04-07 | Plantextrakt Gmbh & Co. Kg | Hopfenextrakt und Verfahren zu dessen Herstellung |
US7736677B2 (en) | 2001-06-20 | 2010-06-15 | Metaproteomics, Llc | Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment |
DE10240065B4 (de) | 2002-08-30 | 2004-10-28 | Hallertauer Hopfenveredlungsgesellschaft M.B.H. | Verfahren zur Gewinnung von in Hopfen enthaltenem Xanthohumol und damit erhältlicher Xanthohumol-reicher Hopfenextrakt |
DE10256031A1 (de) | 2002-11-30 | 2004-06-09 | Nateco 2 Gmbh & Co. Kg | Verfahren zur Herstellung eines Xanthohumol-angereicherten Hopfenextraktes und dessen Verwendung |
DE10256166B4 (de) | 2002-12-02 | 2008-10-23 | Technische Universität München | Verfahren zur Herstellung eines xanthohumolhaltigen Getränkes aus Malz- und/oder Rohfruchtwürze sowie derart hergestelltes Getränk |
DK1431385T3 (da) | 2002-12-18 | 2006-07-31 | Doehler Gmbh | Xanthohumolholdig drik |
-
2013
- 2013-07-26 JP JP2015523566A patent/JP6668073B2/ja active Active
- 2013-07-26 EP EP13742623.5A patent/EP2877167B1/en active Active
- 2013-07-26 CN CN201380039568.8A patent/CN104507463A/zh active Pending
- 2013-07-26 PL PL13742623T patent/PL2877167T3/pl unknown
- 2013-07-26 WO PCT/EP2013/065804 patent/WO2014016409A1/en active Application Filing
- 2013-07-26 KR KR1020157003865A patent/KR20150036604A/ko not_active IP Right Cessation
- 2013-07-26 CN CN201910035406.6A patent/CN109999078A/zh active Pending
- 2013-07-26 US US14/417,193 patent/US9782362B2/en active Active
- 2013-07-26 BR BR112015001595-6A patent/BR112015001595A2/pt not_active Application Discontinuation
- 2013-07-26 HU HUE13742623A patent/HUE052388T2/hu unknown
- 2013-07-26 ES ES13742623T patent/ES2822575T3/es active Active
- 2013-07-26 DK DK13742623.5T patent/DK2877167T3/da active
- 2013-07-26 KR KR1020207022673A patent/KR102219010B1/ko active IP Right Grant
- 2013-07-26 CA CA2880108A patent/CA2880108C/en active Active
-
2015
- 2015-01-27 ZA ZA2015/00598A patent/ZA201500598B/en unknown
- 2015-02-13 IN IN1204DEN2015 patent/IN2015DN01204A/en unknown
-
2018
- 2018-01-05 JP JP2018000662A patent/JP2018087195A/ja active Pending
-
2019
- 2019-12-26 JP JP2019236439A patent/JP7493333B2/ja active Active
-
2022
- 2022-03-31 JP JP2022060371A patent/JP2022104969A/ja active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004089359A1 (ja) * | 2003-04-08 | 2004-10-21 | Kirin Beer Kabushiki Kaisha | 骨密度減少の抑制または予防用組成物および飲食品 |
JP2008524299A (ja) * | 2004-12-22 | 2008-07-10 | テーアー−クサン アーゲー | キサントフモールを含む天然抽出物、およびその製造方法およびそれから製造される製品 |
JP2008532558A (ja) * | 2005-03-25 | 2008-08-21 | ウニベルズィタイト・ヘント | フラボノイド類の酵素的脱メチル化 |
JP2006306800A (ja) * | 2005-04-28 | 2006-11-09 | Kirin Brewery Co Ltd | ファルネソイドx受容体活性化剤 |
JP2009502973A (ja) * | 2005-07-29 | 2009-01-29 | バイオアクティブズ,インコーポレイティド | プレニルフラボノイド製剤 |
JP2009504657A (ja) * | 2005-08-09 | 2009-02-05 | メタプロテオミクス,エルエルシー | ホップ及びアカシア産物によるプロテインキナーゼ調節 |
JP2010513360A (ja) * | 2006-12-22 | 2010-04-30 | ジョー. バース ウント ソーン ゲーエムベーハー ウントコー. カーゲー | 肝疾患を予防および/または制御するための、キサントフモールまたはイソキサントフモールの活性物質としての使用 |
JP2010536772A (ja) * | 2007-08-15 | 2010-12-02 | フラクサン ゲゼルシャフト ミット ベシュレンクテル ハフツング アンド カンパニー ケージー | キサントフモールに富んだホップ抽出物 |
JP2011513308A (ja) * | 2008-02-27 | 2011-04-28 | フラクサン ゲーエムベーハー ウント コー. カーゲー | キサントフモール−シクロデキストリン複合体を含有する新規な組成物 |
Non-Patent Citations (4)
Title |
---|
CANCER LETTERS, vol. Vol.149, No.1-2, JPN6018012288, 2000, pages 21 - 29, ISSN: 0003776191 * |
MUTATION RESEARCH, vol. Vol.632, No.1-2, JPN6018012289, 2007, pages 1 - 8, ISSN: 0003776192 * |
PHYTOMEDICINE, vol. 15, no. 3, JPN6018012290, 2008, pages 216 - 220, ISSN: 0003776193 * |
TOXICOLOGY IN VITRO, vol. 22, no. 2, JPN6018012291, 2008, pages 318 - 327, ISSN: 0003776194 * |
Also Published As
Publication number | Publication date |
---|---|
JP6668073B2 (ja) | 2020-03-18 |
KR20200096702A (ko) | 2020-08-12 |
CA2880108C (en) | 2021-05-18 |
ZA201500598B (en) | 2016-01-27 |
CA2880108A1 (en) | 2014-01-30 |
DK2877167T3 (da) | 2020-10-12 |
PL2877167T3 (pl) | 2021-02-08 |
EP2877167B1 (en) | 2020-07-15 |
KR102219010B1 (ko) | 2021-02-23 |
IN2015DN01204A (ja) | 2015-06-26 |
JP2020090501A (ja) | 2020-06-11 |
JP2018087195A (ja) | 2018-06-07 |
JP2022104969A (ja) | 2022-07-12 |
CN109999078A (zh) | 2019-07-12 |
KR20150036604A (ko) | 2015-04-07 |
JP7493333B2 (ja) | 2024-05-31 |
US20150246008A1 (en) | 2015-09-03 |
CN104507463A (zh) | 2015-04-08 |
HUE052388T2 (hu) | 2021-04-28 |
BR112015001595A2 (pt) | 2018-06-19 |
WO2014016409A1 (en) | 2014-01-30 |
ES2822575T3 (es) | 2021-05-04 |
EP2877167A1 (en) | 2015-06-03 |
US9782362B2 (en) | 2017-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7493333B2 (ja) | 焙煎抽出物およびキサントフモールを含む組成物の使用 | |
EP2007429B1 (en) | Oral formulation with beneficial cardiovascular effects, comprising berberine | |
RU2657757C2 (ru) | НОВЫЕ ЭКСТРАКТЫ ИЗ CYNARA SCOLYMUS, COFFEA spp. И OLEA EUROPAEA ДЛЯ ЛЕЧЕНИЯ МЕТАБОЛИЧЕСКОГО СИНДРОМА | |
AU2018203677A1 (en) | Modified polyphenol compositions | |
JP6046056B2 (ja) | 脱ラムノシルアクテオシド含有オリーブ抽出物 | |
KR101577002B1 (ko) | 울금과 용암해수를 이용한 항콜레스테롤 또는 간기능 개선용 조성물과 기능성 식품 | |
KR101497109B1 (ko) | Ppar 작용 조절 질환의 예방, 개선 또는 치료용 조성물 | |
JP7209193B2 (ja) | 自然発がん予防剤 | |
KR20150097175A (ko) | 발효 더덕 추출물 또는 더덕으로부터 분리된 화합물을 포함하는 비만 또는 비만 관련 질환의 예방, 개선 또는 치료용 조성물 | |
KR20150053321A (ko) | 검정콩 껍질 유래의 안토시아닌을 유효성분으로 함유하는 항비만 조성물 | |
KR100828068B1 (ko) | 푸코잔틴 또는 이를 함유하는 해조류 추출물을 포함하는,고지혈증의 예방 또는 치료용 조성물 | |
US7731994B2 (en) | Pharmaceutical composition for protecting neurons comprising extract of lithospermum erythrothizon SIEB. ET. Zucc or acetylshikonin isolated therefrom as an effective ingredient | |
KR101553109B1 (ko) | 정제봉독을 유효성분으로 함유하는 항바이러스 또는 항종양 조성물 | |
JP4537024B2 (ja) | 炎症疾患予防・治療剤 | |
KR101844455B1 (ko) | 홍마늘을 포함한 항염증 음료 및 환 제조방법 | |
JP2018519342A (ja) | ホップに基づく物質およびその物質の使用 | |
JP2021525222A (ja) | 骨粗しょう症の予防または治療用組成物 | |
JP7242042B2 (ja) | 破骨細胞分化抑制剤並びに骨吸収性疾患の予防・治療・改善用の内服剤又は飲食品組成物 | |
KR102583001B1 (ko) | 클로렐라(Chlorella sp.)추출물 및 이의 페오피틴화 분획물 또는 이로부터 수득한 폴피린계 또는 카로테논계 화합물을 유효성분으로 포함하는 신종코로나 바이러스 감염의 예방 또는 치료용 조성물 | |
KR101576916B1 (ko) | 설퍼레틴을 유효성분으로 포함하는 치수질환 치료 또는 개선용 조성물 | |
JP2023153109A (ja) | ホップ及び白首烏の混合抽出物を有効成分として含む心血管系疾患または骨多孔症の改善用の組成物 | |
JP2009167154A (ja) | 血糖値上昇抑制剤 | |
KR20070075076A (ko) | 티로졸 유도체 화합물을 포함하는 암 질환 예방 및 치료용조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160711 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170404 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170630 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170905 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180105 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20180216 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20180413 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181212 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190116 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190318 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20190731 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191004 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200226 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6668073 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |